Advertisement
GMED vs PAVM
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMED is a Buy and PAVM is a StrongBuy.
GMED in upward trend: price rose above 50-day moving average on October 20, 2026
GMED moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on GMED as a result. In 59 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for GMED just turned positive on September 25, 2026. Looking at past instances where GMED's MACD turned positive, the stock continued to rise in 34 of 50 cases over the following month. The odds of a continued upward trend are 68%.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 198 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
GMED broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GMED entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. GMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.299) is normal, around the industry mean (2.874). P/E Ratio (20.569) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
PAVM's RSI Oscillator is staying in oversold zone for 17 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAVM advanced for three days, in 192 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
PAVM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PAVM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PAVM entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.525) is normal, around the industry mean (2.874). P/E Ratio (-0.120) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (83.333) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. PAVM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PAVM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
GMED | PAVM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 85 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | 54 Fair valued | |
PROFIT vs RISK RATING 1..100 | 98 | 100 | |
SMR RATING 1..100 | 65 | 98 | |
PRICE GROWTH RATING 1..100 | 47 | 95 | |
P/E GROWTH RATING 1..100 | 63 | 99 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PAVM's Valuation (54) in the Medical Specialties industry is in the same range as GMED (79). This means that PAVM’s stock grew similarly to GMED’s over the last 12 months.
GMED's Profit vs Risk Rating (98) in the Medical Specialties industry is in the same range as PAVM (100). This means that GMED’s stock grew similarly to PAVM’s over the last 12 months.
GMED's SMR Rating (65) in the Medical Specialties industry is somewhat better than the same rating for PAVM (98). This means that GMED’s stock grew somewhat faster than PAVM’s over the last 12 months.
GMED's Price Growth Rating (47) in the Medical Specialties industry is somewhat better than the same rating for PAVM (95). This means that GMED’s stock grew somewhat faster than PAVM’s over the last 12 months.
GMED's P/E Growth Rating (63) in the Medical Specialties industry is somewhat better than the same rating for PAVM (99). This means that GMED’s stock grew somewhat faster than PAVM’s over the last 12 months.
| GMED | PAVM | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 82% |
| Stochastic ODDS (%) | 1 day ago 69% | N/A |
| Momentum ODDS (%) | 1 day ago 68% | N/A |
| MACD ODDS (%) | 1 day ago 68% | N/A |
| TrendWeek ODDS (%) | 1 day ago 65% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 61% | 1 day ago 90% |
| Advances ODDS (%) | 11 days ago 64% | 17 days ago 80% |
| Declines ODDS (%) | 5 days ago 58% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 72% | 1 day ago 78% |
| Aroon ODDS (%) | 1 day ago 60% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMED’s FA Score shows that 0 FA rating(s) are green while PAVM’s FA Score has 0 green FA rating(s).
- GMED’s FA Score: 0 green, 5 red.
- PAVM’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMED’s TA Score shows that 4 TA indicator(s) are bullish while PAVM’s TA Score has 3 bullish TA indicator(s).
- GMED’s TA Score: 4 bullish, 4 bearish.
- PAVM’s TA Score: 3 bullish, 2 bearish.
Price Growth
GMED (@Medical/Nursing Services) experienced а +3.58% price change this week, while PAVM (@Medical/Nursing Services) price change was -15.98% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
Reported Earning Dates
GMED is expected to report earnings on Nov 05, 2026.
PAVM is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
PAVM and
Correlation & Price change
A.I.dvisor tells us that PAVM and GMED have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PAVM and GMED's prices will move in lockstep.
| Ticker / NAME | Correlation To PAVM | 1D Price Change % | ||
|---|---|---|---|---|
| PAVM | 100% | -4.65% | ||
| GMED - PAVM | 26% Poorly correlated | +3.79% | ||
| CVRX - PAVM | 25% Poorly correlated | N/A | ||
| RVTY - PAVM | 25% Poorly correlated | +0.48% | ||
| LUCD - PAVM | 25% Poorly correlated | -1.71% | ||
| CSTL - PAVM | 24% Poorly correlated | -3.43% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DJP | 52.01 | -0.02 | -0.04% |
| iPath Bloomberg Commodity Index Total Return ETN (DJP) | |||
| FFDI | 30.52 | -0.49 | -1.59% |
| Fidelity Fundamental Developed International ETF | |||
| QQQ | 704.47 | -20.73 | -2.86% |
| Invesco QQQ Trust Series I (QQQ) | |||
| PIE | 32.06 | -1.81 | -5.36% |
| Invesco Dorsey Wright Emerging Markets Momentum ETF (PIE) | |||
| EGGQ | 43.65 | -3.85 | -8.10% |
| NestYield Visionary ETF (EGGQ) | |||